Gates Foundation extends funding for AN2 Therapeutics-GSK TB drug research collaboration

• AN2 Therapeutics received extended Gates Foundation funding for its tuberculosis R&D collaboration with GSK.
• Funding supports development of boron-based leucyl-tRNA synthetase inhibitors as potential new TB treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260928957267) on September 28, 2026, and is solely responsible for the information contained therein.